Usability study results reaffirm advantages for subcutaneous administration of furosemide with a patch pump

Usability study results reaffirm advantages for subcutaneous administration of furosemide with a patch pump


1 photo

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

HAEGENDORF, Switzerland--(BUSINESS WIRE)--Mar 5, 2014--Sensile Medical AG has completed the usability study for the semi-disposable patch pump that is developed for scPharmaceuticals LLC’s novel subcutaneous furosemide therapy.

Sensile Medical's Patch Pump for scFurosemide (Photo: Business Wire)

In the study health care professionals (HCPs) from seven hospitals in the United States and The Netherlands responded to questions about the subcutaneous application of furosemide ( scFurosemide ® ) in the treatment of heart failure and the handling of Sensile Medical’s new patch pump. The HCPs identified a broad range of clinical situations where scFurosemide treatment may improve both, the care process as well as patients’ outcomes.

The opportunity to treat patients with early stages of decompensation outside the emergency room or hospital emerged as the main advantage of this new scFurosemide treatment option over the current intravenous administration. The study participants expressed a strong interest in the use of the scFurosemide patch pump to better and more cost-effectively manage patients with heart failure.

“Using these devices with scFurosemide ® patients will be able to initiate effective treatment earlier when symptoms deteriorate.” said Rudolf Sidler, PhD, Product Manager at Sensile Medical. “In many cases this may prevent a visit to the emergency room or need for in-patient stay.“

“We are very pleased with the results of the study. They confirmed that we are on the right track with this unique combination product.” said Pieter Muntendam, MD, President and CEO of scPharmaceuticals. “Sensile’s precise micro pump technology enables a new generation of cost-effective devices previously not possible.”

Sensile Medical and scPharmaceuticals entered into a strategic partnership and supply agreement in the first quarter of 2013. The successful completion of this development milestone paves the way for the company’s first regulatory filings in 2015.

About Sensile Medical

Sensile Medical AG is a leading company in the area of advanced micro pump technology developing a broad range of customer-specific delivery and dosing solutions. Due to Sensile's SenseCore technology the products are highly cost-efficient, accurate, and safe. They are increasingly used in medical, industrial, and consumer applications. Founded in 2004, Sensile Medical is located in Haegendorf, Switzerland. For further information consult www.sensile-medical.com.

Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20140305005036/en/

CONTACT: Sensile Medical AG

Lars G. Krinelke, MD, PhD

Head of Product Management

Phone +41622097100

Fax +41622097101

lars.krinelke(at)sensile-medical.com

www.sensile-medical.com

KEYWORD: EUROPE SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY HOSPITALS MEDICAL DEVICES PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Sensile Medical AG

Copyright Business Wire 2014

PUB: 03/05/2014 04:00 AM/DISC: 03/05/2014 04:00 AM

http://www.businesswire.com/news/home/20140305005036/en

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Photos

Sensile Medical Ag

    SIGN UP FOR THE KSL.COM NEWSLETTER

    Catch up on the top news and features from KSL.com, sent weekly.
    By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

    KSL Weather Forecast